Metraipolis › archive › dc_cf8bedd87b46

Real-world insights into incidence and risk factors of thyroid dysfunction following immune checkpoint inhibitor therapy — Europe PMC PMID:42630547

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42630547
DOI
10.3389/fimmu.2026.1882182
License (as archived)
solo-consultazione
Archived
2026-10-08T01:24:03.061Z
SHA-256 of the archived text
63a79959a4de5b7477f9288855277650b62699606ecb7a0ae4d4c12bfd9d1d46
Stable URL of this page
https://metraipolis.com/documento/dc_cf8bedd87b46

How to cite

Real-world insights into incidence and risk factors of thyroid dysfunction following immune checkpoint inhibitor therapy — Europe PMC PMID:42630547 — Europe PMC (en), https://europepmc.org/article/MED/42630547 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cf8bedd87b46 (Metraipolis archive dc_cf8bedd87b46, sha256 63a79959a4de5b7477f9288855277650b62699606ecb7a0ae4d4c12bfd9d1d46)
BibTeX
@misc{dccf8bedd87b46,
  title = {Real-world insights into incidence and risk factors of thyroid dysfunction following immune checkpoint inhibitor therapy — Europe PMC PMID:42630547},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42630547},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cf8bedd87b46; sha256 63a79959a4de5b7477f9288855277650b62699606ecb7a0ae4d4c12bfd9d1d46},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42630547. Agents can read the archived copy with the MCP tool read_document.